Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 263

Similar articles for PubMed (Select 11751522)


Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK.

Clin Cancer Res. 2001 Dec;7(12):4209-19.


Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK.

Cancer Res. 2002 Jul 15;62(14):3950-5.


The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6052-61.


Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin.

Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan KV, Pantazis P, Wyche JH.

J Biol Chem. 2002 May 10;277(19):17154-60. Epub 2002 Mar 4.


Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.

Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.

Oncogene. 2002 May 16;21(22):3611-9.


The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.

Ambrosini G, Seelman SL, Qin LX, Schwartz GK.

Cancer Res. 2008 Apr 1;68(7):2312-20. doi: 10.1158/0008-5472.CAN-07-2395.


Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.

Allegrini G, Goulette FA, Darnowski JW, Calabresi P.

Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.


The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD.

Int J Cancer. 2009 Dec 15;125(12):2957-69. doi: 10.1002/ijc.24658.


Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.

Darpolor MM, Kennealey PT, Le HC, Zakian KL, Ackerstaff E, Rizwan A, Chen JH, Sambol EB, Schwartz GK, Singer S, Koutcher JA.

NMR Biomed. 2011 Nov;24(9):1159-68. doi: 10.1002/nbm.1674. Epub 2011 Mar 24.


Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.

Clin Cancer Res. 2008 Apr 1;14(7):2180-9. doi: 10.1158/1078-0432.CCR-07-1392.


Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.

Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A.

Jpn J Cancer Res. 1997 Aug;88(8):760-9. Erratum in: Jpn J Cancer Res 1997 Sep;88(9):919.


CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.

Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E.

Int J Cancer. 1997 Jan 27;70(3):335-40.


Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.

Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA.

Blood. 1998 Apr 1;91(7):2482-90.


Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S.

Cancer Res. 1999 Mar 1;59(5):1049-53.


PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.

Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, Rosen GD.

Mol Cancer Ther. 2003 Sep;2(9):855-62.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk